Therapeutic Expertise

004 syringe

Vaccine Development

Prophylactic and therapeutic vaccines against viral, bacterial, and parasitic pathogens.

010 antivirus

Antimicrobial & Antiviral Agents

Novel anti-infective compounds, resistance mechanisms, and combination therapies.

003 mask

Emerging & Re-emerging Pathogens

COVID-19, Zika, Ebola, dengue, RSV, influenza, and other outbreak-prone diseases.

006 chemistry

Immunologic & Host-Targeted Therapies

Immunomodulators and adjuvants designed to enhance host response.

Clinical Trial Capabilities

025 science book

Phase I–IV Clinical Trials

Design and execution of first-in-human, dose-ranging, safety, efficacy, bridging, and post-marketing studies.

016 museum

Regulatory Affairs & Strategy

Early engagement with Health Canada, FDA, EMA, and regional authorities to streamline submissions and approvals.

020 server

Data & Biomarker Integration

Immunogenicity, pharmacokinetic/pharmacodynamic (PK/PD), and correlates of protection analyses.

023 ebook 1

Rapid Study Activation in Outbreaks

Leveraging site readiness and accelerated contracting for time-sensitive and emergent disease contexts.

Operational Infrastructure

033 group

Site Partnerships

Collaboration with academic, hospital-based, and community research sites.

035 cloud setting

Centralized Data Management

Real-time electronic data capture (EDC), remote monitoring, and adaptive analytics.

Verified

Experienced Investigators

Infectious disease specialists, vaccinologists, and epidemiologists with proven expertise in protocol delivery.

041 diploma

Quality & Compliance Systems

GCP-aligned processes ensuring accuracy, transparency, and regulatory readiness.

Partner With Us

Conduct Research Inc. supports pharmaceutical, biotech, and public health organizations in advancing infectious disease and vaccine programs from concept to market.

Scientific & Medical Affairs

 

Conduct Research Inc.’s scientific and medical affairs unit provides strategic input at every stage of study planning and execution:

  • Protocol design and endpoint development

  • Selection and validation of immunologic assays

  • Risk-benefit assessment and data review

  • Medical monitoring and pharmacovigilance

  • Clinical data interpretation and publication support

Our experts also collaborate on translational research initiatives that connect early discovery with late-phase clinical outcomes.

Strategic Advantages

Partnering with Conduct Research Inc. offers sponsors measurable advantages in infectious disease and vaccine development:

  • Scientific depth across virology, immunology, and epidemiology

  • Accelerated timelines through adaptive design and rapid start-up models

  • Integrated SMO–CRO model ensuring site performance and data consistency

  • Regulatory and ethical expertise supporting global submissions

  • Commitment to diversity and equity in participant recruitment and representation